Isabelle Le Mercier

Isabelle Le Mercier

Auto-generated profile, based on publicly available information

Isabelle Le Mercier

KSQ Therapeutics, 4 Maguire Road, Lexington, MA 02421

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2025 in Blood
Verified
Journal Article
Closed access
BKBrent H. Koehn
Brent H. Koehn
ENElizabeth C. Nowak
Elizabeth C. Nowak
SSSladjana Skopelja-Gardner
Sladjana Skopelja-Gardner
ASAsim Saha
Asim Saha
MZMichael C. Zaiken
Michael C. Zaiken
BBBruce R. Blazar
Bruce R. Blazar
The success of allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be limited by graft-versus-host disease (GVHD). T-cell activation is a key factor in GVHD progression. Costimulatory signals can be counterbalanced by coinhibitory signals such as the checkpoint molecule VISTA (V-domain immunoglobulin-containing suppressor of T-cell activation)/programmed death-1 homolog that restrains activation and maintains donor T-cell quiescence. A single dose of anti-VISTA monoclonal antibody (mAb) prevents acute GVHD lethality in multiple models. Naïve donor T cells express moderate VISTA levels, which transiently increase in allo-HSCT recipients in association with T-cell receptor signaling, leading to heightened susceptibility to anti-VISTA mAb–mediated depletion, in contrast to donor T cells transferred to syngeneic recipients. Anti-VISTA mAb donor T-cell depletion was compatible with rapamycin but incompatible with peritransplant tacrolimus GVHD prophylaxis. Targeting VISTA exclusively on host cells or donor CD8+ T cells was not protective against GVHD lethality. Instead, anti-VISTA mAb–mediated deletion of alloreactive donor T cells depended on targeting a third (non-T) cell type. Further mechanistic studies indicated that donor T cells concurrently exposed to anti-VISTA mAb in vivo but not preincubated in vitro before adoptive T-cell transfer were eliminated via Fc receptor (FcR)-mediated phagocytosis. In a lymphoma challenge model, a graft-versus-lymphoma (GVL) effect was fully retained when anti-human VISTA mAb exclusively targeted donor CD4+ T cells, and was delayed but mostly retained when unseparated donor T cells were infused. In a xenogeneic GVHD model, anti-human VISTA mAb reduced donor T-cell expansion, VISTA T-cell expression levels, and recipient lethality. Together, these data support a novel clinical translational pathway in which acute GVHD lethality can be mitigated without negating the GVL effect.

1 July 1994 in Human Immunology
Verified
Journal Article
Closed access
CPChristine Pouletty
Christine Pouletty
IMIsabelle Mercier
Isabelle Mercier
LGLinda Glanville
Linda Glanville
NTNathalie Tomavo
Nathalie Tomavo
LILev Igoudin
Lev Igoudin
RBRoland Buelow
Roland Buelow

1 November 1992 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
JLJ. LeBlanc
J. LeBlanc
IMI. Mercier
I. Mercier
The bradycardia induced by cold wind blown on the face and the early cephalic release of insulin induced by feeding have been shown to be caused by a vagal reflex stimulation. An experiment was designed to determine whether cold wind blown on the face would induce both pancreatic and cardiac stimulation. A 4 degrees C wind blown on the face for 4 min produced a rapid and persistent bradycardia, which interestingly persisted for up to 35 min after the test. The effect on respiration rate is more gradual and vanishes immediately after cold wind stimulation. Cold wind produced a slight reduction of insulin secretion, as evidenced by the fall of both plasma insulin and C-peptide, and caused a significant increase in plasma norepinephrine. These results suggest that the cold wind action of the vagus nerve is exerted on the heart and that of the sympathetic on the pancreas, whereas during the cephalic phase of feeding a vagal influence is observed on the pancreas and a sympathetic action on the heart. The mechanisms of the quantitative and qualitative control of these autonomic responses are not known and deserve further investigation.

23 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
IMIsabelle Le Mercier
Isabelle Le Mercier
DMDavid Monteiro
David Monteiro
KHKatarina Halpin-Veszeleiova
Katarina Halpin-Veszeleiova
KWKarrie Wong
Karrie Wong
ADAnne Dodson
Anne Dodson
MBMicah J. Benson
Micah J. Benson
The solid tumor microenvironment inhibits the functionality of tumor infiltrating T cells recognizing cognate tumor antigen, driving their differentiation towards terminal exhaustion. Interventions are sought to enhance the anti-tumor functionality of tumor-reactive T cells for clinical benefit. The functional genome regulating CD8 + T cell function against solid tumors was mapped by performing genome-wide, focused, and combination in vivo CRISPR/Cas9 screens using OT1 and PMEL TCR transgenic T cells in B16-OVA, MC38-gp100 and EG7-OVA syngeneic tumor models. The ability of the top single hits and combinations, which include Regnase-1 and SOCS1, to enhance CD8 + T cell anti-tumor function was evaluated in the OT1/B16-OVA model with large and established tumors, the disseminated PMEL/B16F10 tumor model, and in a novel murine TIL syngeneic model. The impact of Regnase-1 and SOCS1 single and dual-inactivation on the differentiation of exhausted CD8 + T cell subsets and on long-term persistent memory following tumor clearance was evaluated in OT1 CD8 + T cells in the B16-OVA model. The impact of single and dual-inactivation of Regnase-1 and SOCS1 on the anti-tumor function of experimental human T cell therapeutics was characterized in CRISPR/Cas9-engineered human TIL derived in vitro and in mesothelin-targeting CAR-Ts in vivo. NF-κB and cytokine signaling were identified as the top pathways regulating CD8 + T cell anti-tumor function, with Regnase-1 and Suppressor of Cytokine Signaling 1 (SOCS1) the top single and combination edits regulating the accumulation of tumor-specific TCR transgenic CD8 + T cells in syngeneic tumor models. Dual-inactivation of Regnase-1 and SOCS1 cooperated through non-redundant mechanisms to strongly expand intermediate (Tex int ) and effector (Tex eff ) exhausted CD8 + T cells within lymphoid tissues and tumor, with CD8 + T cells rewired to display an enhanced effector state and suppressed expression of TOX. Dual-edited persistent T effector memory cells (T em ) were formed following tumor clearance. Lastly, Regnase-1 and SOCS1 inactivation enhanced human Tumor Infiltrating Lymphocyte (TIL) and chimeric antigen receptor T cells (CAR-T) therapy functionality. Collectively, this study systematically mapped pathways regulating CD8 + T cell anti-tumor functionality, with Regnase-1 and SOCS1 dual-inactivation found to maximize anti-tumor function through non-redundant mechanisms.

4 April 2023
Verified
Other
Open access
JDJie Deng
Jie Deng
JLJiannan Li
Jiannan Li
ASAurelien Sarde
Aurelien Sarde
JLJ. Louise Lines
J. Louise Lines
YLYu-Chi Lee
Yu-Chi Lee
RMRodwell Mabaera
Rodwell Mabaera
Figure S2. Vista expression is correlated with myeloid infiltration in the TME of colon cancer patients. Volcano plot of CLS differences (granulocytic, monocytic, and αβ T cells) between VISTAhigh and VISTAlow cohorts and the associated significance values obtained using Mann-Whitney tests.

30 March 2023
Verified
Other
Open access
IMIsabelle Le Mercier
Isabelle Le Mercier
WCWenna Chen
Wenna Chen
JLJanet L. Lines
Janet L. Lines
MDMaria Day
Maria Day
JLJiannan Li
Jiannan Li
LWLi Wang
Li Wang
PDF file - 11K, The serum clearance and immunogenicity of VISTA-specific hamster monoclonal antibody 13F3.